| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, and
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B. Blocking p38 inhibits LPS-induced maturation of DCs. In this study we investigated the role of LPS in the in vitro generation of immature DCs. We report here that in contrast to the observed beneficial effects on DCs, the presence of LPS in monocyte culture retarded the generation of immature DCs. LPS not only impaired the morphology and reduced the yields of the cultured cells, but also inhibited the up-regulation of surface expression of CD1a, costimulatory and adhesion molecules. Furthermore, LPS up-regulated the secretion of IL-1
, IL-6, IL-8, IL-10, and TNF-
; reduced Ag presentation capacity; and inhibited phosphorylation of ERK, but activated p38, leading to a reduced NF-B activity in treated cells. Neutralizing Ab against IL-10, but not other cytokines, partially blocked the effects of LPS. Inhibiting p38 (by inhibitor SB203580) restored the morphology, phenotype, and Ag presentation capacity of LPS-treated cells. SB203580 also inhibited LPS-induced production of IL-1, IL-10, and TNF-; enhanced IL-12 production; and recovered the activity of ERK and NF-B. Thus, our study reveals that LPS has dual effects on DCs that are biologically important: activating existing DCs to initiate an immune response, and inhibiting the generation of new DCs to limit such a response. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The maturation process is central to the function of the DCs and enables one cell to perform different, highly specialized functions sequentially. There are many stimuli that can initiate this maturation process in vitro. These include the proinflammatory cytokines TNF- and IL-1, ligation of CD40 by CD40 ligand or anti-CD40 Abs, and bacterial products (2, 3, 4). LPS, a Gram-negative bacterial cell wall component, has been shown to fully activate DCs both in vitro and in vivo. The activation of DC by LPS or LPS-induced inflammatory products up-regulates the expression of surface MHC class I and II, costimulatory and adhesion molecules CD40, CD54, CD80, and CD86, and eventually results in the development of an Ag-specific T cell response (5, 6). Although significant progress has been made over the past several years (7, 8, 9, 10), signal transduction pathways involved in (LPS-induced) maturation of DCs are still poorly characterized. It has been shown that LPS interacts with immature DCs through the surface receptor Toll-like receptor-4 (TLR-4), leading to activation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinases (MAPKs), and NF-B (7, 8) and production of IL-12 (4, 11). Blocking NF-B or MAPK p38 inhibits LPS-induced maturation of DCs, indicating that NF-B and p38 MAPK play pivotal roles in the process.
Although LPS has been identified as an activation and maturation agent for DCs, its role in the differentiation and generation of immature DCs from their precursor cells has not been well studied (12, 13). The establishment of in vitro culture systems, allowing the induction of human DCs from various precursors, offers the possibility to study molecular mechanisms involved in DC differentiation. This study investigated the effects of LPS on the generation of immature, monocyte-derived DCs (MoDCs) and the molecular events that accompany this. Like DCs, monocytes express LPS receptor TLR-4 (14) and, in addition, CD14 (15), both of which are able to interact with LPS. Furthermore, it has been shown that a portion of lymph node DCs is derived from monocytes in vivo (16). Thus, such an in vitro study is biologically relevant and important. We show that in contrast to the observed activating effect on already differentiated DCs, LPS retarded the generation of immature MoDCs; addition of LPS to the culture reduced cell yields, impaired their morphology and phenotype, and compromised their Ag presentation capacity. We also show that p38 MARK plays an important role in these events, since inhibition of p38 restored the generation of functional, immature DCs. Thus, our study identifies LPS as a negative regulator in the differentiation of DCs.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
LPS and FITC-dextran were obtained from Sigma-Aldrich (St. Louis, MO). Protease inhibitor cocktail; PE- or FITC-conjugated mAbs against HLA-ABC, HLA-DR, CD1a, CD83, CD80, CD86, CD54, and CD40; mouse Ig G1 isotype control; and neutralization Abs against TNF-, IL-10, and IL-6 were purchased from BD PharMingen (San Diego, CA). Anti-CD14 Ab-conjugated microbeads were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Polyclonal Abs against IB and IB were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and Abs against MAPKs, phosphorylated IB, and STAT3 at Tyr705 were obtained from Cell Signaling Technology (Beverly, MA). Recombinant IL-1, IL-4, GM-CSF, and TNF- were purchased from R&D Systems (Minneapolis, MN). Tuberculin purified protein derivative (PPD) was purchased from Statens Serum Institute (Copenhagen, Denmark). SB203580 (specific p38 MAPK inhibitor) was obtained from Calbiochem-Novabiochem (La Jolla, CA). [3H]Thymidine and Ficoll-Hypaque were purchased from Amersham Pharmacia Biotech (Piscataway, NJ).
Generation of MoDCs
MoDCs were generated from peripheral blood monocytes using the standard protocols (5, 17). Briefly, PBMCs were isolated from blood of healthy donors using Ficoll-Hypaque gradient centrifugation. In most of the studies MoDCs were obtained by incubating PBMCs on plastic surface at 37°C in 5% CO2 for 2 h to allow monocyte adhesion. After incubation, nonadherent cells were removed, and plates were vigorously washed (at least three times) to get rid of contaminating cells. In some experiments monocytes were purified from PBMCs by positive selection using a MACS column with anti-CD14 Ab-conjugated microbeads. The positively selected fraction contained >95% CD14+ monocytes. The adherent cells or purified CD14+ cells were suspended in RPMI 1640 supplemented with 10% FCS, 1 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, GM-CSF (100 ng/ml), and IL-4 (100 ng/ml) in a humidified incubator at 37°C in 5% CO2, with further addition of cytokines every other day by replacing 50% of the medium with fresh medium containing the cytokines. After 7 days of culture, immature MoDCs were harvested for testing. To induce maturation, LPS (1 µg/ml) or TNF- (10 ng/ml) and IL-1 (10 ng/ml) were added to 7-day cultures, and cells were incubated for an additional 48 h. On day 9 mature MoDCs were harvested for analysis. To examine the effects of LPS on in vitro generation of MoDCs, LPS was added at the beginning of the culture. No additional LPS was added during the 7 days when medium was changed.
Flow cytometric analysis
Cells harvested on days 7 and 9 were analyzed for their surface expression of relevant molecules. This was conducted using a FACScan (BD Biosciences, San Jose, CA). Briefly, cells were first washed twice in PBS, followed by addition of PE- and FITC-conjugated mAbs. After incubation on ice for 30 min the cells were washed twice, resuspended in PBS, and prepared for analysis. Controls consisted of cells stained with irrelevant mouse IgG Abs.
Measurement of cytokines by cytometric bead array analysis
Kits of cytometric bead array analysis for the detection of cytokines (18), including IL-1, IL-6, IL-8, IL-10, IL-12, and TNF- (inflammatory cytokine kit), and IL-2, IL-4, IL-5, IL-10, IFN-
, and TNF- (T cell subset cytokine kit), were purchased from BD PharMingen, and assay was performed by the Core Facility at Department of Microbiology and Immunology, University of Arkansas for Medical Sciences. Briefly, supernatants of monocyte or T cell culture were collected and kept frozen at -80°C until analysis. When assayed, the supernatants were mixed with human cytokine-captured beads, and PE-conjugated detection reagent was added and incubated for 3 h at room temperature. After the incubation, the beads were washed three times, resuspended in PBS, and prepared for flow cytometric analysis.
Endocytic activity assay
To evaluate the capacity for uptake via mannose receptor-mediated endocytosis, cultured cells or MoDCs were incubated with 1 mg/ml FITC-dextran at 37 or at 0°C (control for autofluorescence intensity) for 1 h (8, 12) and then washed four times with ice-cold PBS. Cells were analyzed by flow cytometer.
Allogeneic MLR assay
To examine the capacity of MoDCs or LPS-treated cells to activate allogeneic T cells, an allogeneic MLR was used. Briefly, purified allogeneic T cells (8 x 104 cells/100 µl/well) were seeded in 96-well, U-bottom tissue culture plates. MoDCs or LPS-treated cells in various numbers were added and cultured at 37°C in 5% CO2 for 6 days. Sixteen hours before harvest, 1 µCi of [3H]thymidine was added to each well. Cells were harvested, and radioactivity was measured in a beta-liquid scintillation analyzer (Packard, Meriden, CT). Results are expressed as the mean counts per minute of triplicate cultures.
Presentation of soluble Ag by MoDCs
To examine the capacity of MoDCs and LPS-treated cells to capture and present soluble Ag and to activate autologous Ag-specific T cells, an assay of the T cell response to recall Ag PPD was performed. This was conducted with cells from healthy blood donors who had been immunized with bacillus Calmette-Guérin vaccines and showed a positive T cell proliferative response against PPD in vitro. The cultured cells were pulsed with 2.5 µg/ml of PPD for 2 h, washed three times with PBS, and cultured with purified autologous T cells for 6 days. The T cell proliferative response was measured by overnight incubation with [3H]thymidine (1.0 µCi/well), as described for the MLR assay.
Western blot analysis
To detect intracellular signaling associated with LPS treatment, Western blots were used to analyze MAPKs, NF-B, and STAT3 expression by cultured cells. To detect MAPKs, IB, and IB, cells were cultured with or without LPS, harvested, washed, and lysed with lysis buffer (50 mM Tris (pH 7.5), 140 mM NaCl, 5 mM EDTA, 5 mM Na3N3, 1% Triton X-100, 1% Nonidet P-40, and 1x protease inhibitor cocktail). For the determination of phosphorylated MAPKs, IB, and STAT3 (Tyr705), cells were lysed directly in Laemmli buffer (Sigma-Aldrich). The samples were centrifuged at 12,000 x g, and the supernatants were collected, boiled, and subjected to SDS-PAGE. After transfer to nitrocellulose membrane and subsequent blocking, the membranes were immunoblotted with respective Abs against phosphorylated MAPKs, IB, or STAT3 and visualized with alkaline phosphatase-conjugated secondary Abs, followed by enhanced chemiluminescence (Bio-Rad Laboratories, Hercules, CA). For protein quantification, blots were scanned and analyzed by spot densitometry using the Alphalmager 2200 Documentation and Analysis System ( Innotech, San Leandro, CA). The results are expressed as the average value of pixels enclosed (AVG). AVG is calculated as the sum of all pixel values after background correction divided by area.
Statistical analysis
Student’s t test was used to compare various experimental groups; significance was set at p < 0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To examine its effects on in vitro generation of immature MoDCs, LPS was added at the beginning of cell culture at a low dose (1 ng/ml) that mimics the blood endotoxin concentrations seen in severe sepsis (19) and at a high dose (1 µg/ml) that has been the commonly used dose to induce DC maturation in vitro (13, 20). In all experiments LPS was continuously present in the cultures, although its concentrations were gradually decreased due to medium change every 2 days without further addition of the endotoxin. Fig. 1 depicts the morphology of control MoDCs and LPS-treated cells cultured for 7 days in medium with or without addition of LPS. It is evident that the presence of endotoxin in culture medium affected cell morphology; cells cultured with LPS at both doses were smaller, with poorly differentiated, macrophage-like morphology, while cells cultured in medium without LPS appeared as mostly floating, single cells with enlarged, DC-like morphology. In addition, a lower cell yield, determined by viable large cell count, was obtained in cultures with LPS (p < 0.05 for both concentrations; Fig. 2A). We next examined whether induction of apoptosis by LPS was responsible for the low cell yield. It was analyzed using flow cytometric analysis with FITC-conjugated annexin V and propidium iodide. No difference was observed between the cultures with or without LPS (data not shown), suggesting that LPS did not induce apoptosis in treated cells; instead, fewer cells were differentiated into large, immature MoDCs in the presence of LPS. Thus, cells recovered from the cultures with the addition of LPS are referred to in this study as LPS-treated cells, not as MoDCs. In these and the following studies, PBMCs from five healthy blood donors were used to generate immature MoDCs.
|
|
(p < 0.01), IL-6 (p < 0.01), IL-8 (p < 0.01), IL-10 (p < 0.01), and TNF- (p < 0.05) by cultured cells. The concentration of IL-12 was low (
1 pg/ml) in medium and was slightly up-regulated by the addition of LPS (IL-12, 3–9 pg/ml; p < 0.05). We next examined the surface expression of DC-related molecules on cultured cells. After 7-day culture, cells were washed three times and stained with PE- and FITC-conjugated Abs. As shown by the representative histograms of flow cytometric analysis of cultured cells (Fig. 3), surface expression of CD1a, CD40, CD54, CD80, and CD86 was significantly (1.4- to 2.3-fold; p < 0.05 and p < 0.01) lower on 1 µg/ml LPS-treated cells. The effects of LPS at 1 ng/ml on these cells were similar, but less pronounced (data not shown). The expression of HLA-ABC and -DR on LPS-treated cells was also lower, but not significantly different from that on control MoDCs.
|
|
B and higher STAT3 activity in treated cells
As MAPKs play a critical role in the regulation of cell growth and differentiation, and NF-B and STAT3 are involved in the regulation of cytokine expression of or response to cytokines such as IL-6 and IL-10, we examined the levels and activity of these molecules by Western blot analysis. Cell lysates collected on days 1, 3, and 5 of the cultures were prepared for the analyses. Highly purified monocytes were used in these experiments to generate immature MoDCs. In this study the expression of MAPK family members, i.e., the phosphorylated ERK, p38 MAPK, and stress-activated protein kinase/JNK was examined, as were the nonphosphorylated MAPKs, which could serve as controls for protein loading. As shown in Fig. 5, compared with controls, significantly higher levels of phosphorylated p38 (pp38) were observed in cells treated LPS (at both 1 ng/ml and 1 µg/ml) on days 1 and 3 (p < 0.01 and p < 0.05; Fig. 5, A and B), which gradually declined thereafter. In contrast, a lower level of phosphorylated ERK1 and ERK2 (pERK) was observed in cells treated with LPS on days 1 and 3 (p < 0.01 and p < 0.05), but it gradually increased in treated cells thereafter (Fig. 5, A and C). During culture the levels of pERK were high and remained stable in control cells. The levels of nonphosphorylated p38, ERK, and MAPK kinase (MEK) remained stable (Fig. 5A). No changes were observed in the expression of stress-activated protein kinase/JNK (data not shown). These findings indicate that while monocytes cultured in the presence of IL-4 and GM-CSF expressed a relatively high level of pERK and a low level of p38, the addition of LPS to the culture up-regulated the expression of p38 and down-regulated that of pERK. As the exogenous LPS was consumed or diluted, because no additional endotoxin was added during the culture when 50% of the medium was replaced every 2 days, the expression of pp38 and pERK gradually returned to the levels seen in control cells.
|
To detect NF-B activity, we examined the expression or activity of its inhibitors, IB, IB, and phosphorylated IB (pIB), since phosphorylation of serine residues on the IB proteins (appeared as elevated levels of pIB) by kinases marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-B complex (16). Compared with those in medium only, cells cultured in the presence of LPS had higher levels of pIB (Fig. 5, A and E), but lower levels of IB (Fig. 5, A and F) on day 1, which gradually decreased (pIB) or increased (IB), respectively, in cells treated with 1 µg/ml of LPS during culture. This suggests that NF-B activity was high in LPS-treated cells on day 1, but declined thereafter. In contrast, the levels of pIB were lower, and those of IB were higher in control cells on day 1; during culture the levels of pIB gradually increased, and those of IB decreased, respectively, suggesting an enhanced activity of NF-B during cell differentiation induced by IL-4 and GM-CSF. The level of IB remained stable (Fig. 5A). Collectively, these findings indicate that while NF-B activity was low in starting monocytes and was up-regulated gradually during cell differentiation to immature MoDCs, its activity in LPS-treated cells was high initially, but decreased thereafter.
Neutralizing IL-10 partially blocked the effects of LPS on the generation of immature MoDCs
The results to date demonstrate that LPS impaired in vitro generation of immature MoDCs. It was conceivable that the inflammatory cytokines, such as IL-6, TNF-, and IL-10, and MAPKs, especially p38, were involved. To examine the effects of these cytokines on the generation of immature MoDCs, neutralizing Abs against IL-6, TNF-, and IL-10 were used. It appeared that neutralizing Ab against IL-10, but not to the other two cytokines, had a minor effect, as addition of the Ab (20 µg/ml) to culture partially restored LPS-inhibited surface expression of DC-related molecules, such as CD1a and CD54 (Fig. 6). However, all these Abs were potent at neutralizing their respective cytokines, as revealed by the cytometric bead array analysis (data not shown). The combination of these neutralizing Abs had no synergistic effects (data not shown). In line with these results, addition of exogenous IL-10 (10 ng/ml), but not the other cytokines, to the culture also impaired, although to a lesser extent, the generation of immature MoDCs (data not shown). Thus, these observations indicate that IL-10 plays a role in the LPS-induced alterations seen in treated cells.
|
We next examined the importance of p38 in LPS-induced alterations in DCs. A p38 inhibitor, SB203580, was chosen, which was added (10 µM) (9, 21) to the cells at the beginning of the culture. In these and the following experiments LPS at 1 µg/ml was used to retard the generation of immature MoDCs. Our results show that inhibition of p38 MAPK in LPS-treated cells not only restored the morphology (Fig. 1) and phenotype (Fig. 3) of the cultured cells, but also significantly inhibited the up-regulation of IL-1 (p < 0.05), TNF- (p < 0.01), and IL-10 (p < 0.01), but not IL-8, production induced by LPS (Fig. 2, B and C). Interestingly, the inhibitor SB203580 further up-regulated IL-12 (6-fold; p < 0.01) and IL-6 (1.2-fold; p > 0.05) production by the cells in response to LPS (Fig. 2 B and C).
Inhibition of p38 MAPK in LPS-treated cells also enhanced their Ag uptake and presentation capacity. As shown in Fig. 7A, SB203580 treatment completely restored FITC-dextran uptake by LPS-treated cells. In addition, these cells had the same capacity to stimulate allospecific T cells (Fig. 7B) and to present recall Ag PPD and activate PPD-specific, autologous T cells (Fig. 7C) as the control MoDCs. Hence, inhibition of p38 MAPK restored not only the morphology and phenotype, but also the function of LPS-treated cells. These results confirm that p38 MAPKs play a crucial role in LPS-induced retardation in the generation of functional MoDCs.
|
B and down-regulated that of IB (Fig. 8, A and B), indicating that inhibition of p38 led to enhanced NF-B activity in LPS-treated cells. The level of IB remained stable. Taken together, these findings suggest that LPS binding to cell surface receptors activates p38, which inactivates the (Raf/MEK/)ERK MARK pathway, leading to reduced NF-B activity, and impaired the differentiation of monocytes to immature MoDCs. Inhibiting p38 activity overcomes the negative effects of LPS on the cells.
|
We wondered whether maturation of cultured cells with LPS or cytokines TNF- and IL-1 for an additional 48 h could correct the defects caused by LPS treatment. In these experiments immature MoDCs or cultured cells were generated in medium with or without addition of LPS at 1 µg/ml. On day 7 cells were washed, and LPS (1 µg/ml) or recombinant TNF- and IL-1 (5, 17) were added to induce DC maturation. After 48 h cells were harvested and analyzed for their phenotype. As shown in Fig. 9, cells cultured in the absence of LPS for the first 7 days significantly (4- to 32-fold) up-regulated, compared with control immature MoDCs (see Fig. 3), the expression of CD40, CD83, CD80, CD86, and MHC class I and II molecules after 48-h culture with LPS, while cells cultured in the presence of LPS for the first 7 days displayed poor morphology (data not shown) and phenotype after maturation. Addition of the p38 inhibitor SB203580 to the culture restored, to a large extent, the phenotype of a mature DC. Similar effects were obtained with TNF- and IL-1 on mature DCs (data not shown). Thus, these results indicate that the damage caused by LPS during the differentiation of monocytes remained after maturation.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, IL-6, IL-8, and TNF- and the immunosuppressive cytokine IL-10 and reduced the cells’ capacity to take up particulate Ags, activate allospecific T cells, present recall Ag PPD, and activate autologous, PPD-specific T cells. These defects were sustained after an additional 48-h culture with LPS or with TNF- and IL-1 to induce maturation of these cells. Collectively, these findings indicate that LPS is detrimental to the differentiation of immature DCs from blood monocytes. Thus, our study identifies LPS as a negative regulator of DC differentiation. Further study is needed to examine whether LPS could also affect the differentiation of immature DCs from CD34+ stem cells. DCs are professional APCs that represent the essential link between innate and acquired immunity (2). DCs express different TLRs that function as pattern recognition receptors specific for microbial pathogens, such as LPS, lipoproteins, and bacterial DNA (14, 22, 23). During infection, signaling through TLRs triggers DC maturation, which results in the increase in surface expression of MHC class I and II, costimulatory and adhesion molecules and the production of numerous proinflammatory cytokines that are essential for initiating T cell-mediated immune responses. On the other hand, our study demonstrates that in the presence of LPS the differentiation and generation of immature MoDCs were retarded, indicating that LPS also has a negative effect on DCs or their precursor cells. Conceivably, both effects are biologically important and required. By activating existing DCs, LPS is able to facilitate the generation of a beneficial antibacterial immune response to eliminate the infection, and by inhibiting the generation of new immature DCs, it can also limit the scale of the immune response to minimize damage to normal tissue. Hence, LPS can act as both positive and negative regulators of the immune system.
The signaling pathways involved in LPS-induced DC maturation seem to differ from those involved in LPS-induced retardation of DC precursor differentiation. It is known that interaction of LPS with TLR-4 on immature DCs leads to phosphorylation and activation of all three MAPKs, i.e., ERK, JNK and p38, and NF-B (7, 8, 9, 10). Blocking NF-B or p38 inhibits DC maturation induced by LPS, indicating that activation of p38 MARK and NF-B is essential for DC maturation (8, 24, 25). In our study, however, the interaction of LPS with its surface receptors on monocytes activated MAPK p38, but reduced the expression of phosphorylated ERK. No change was noted with SAK/JNK. In addition, such an interaction led to a reduced activity of NF-B, but activated STAT3 in treated cells. These results suggest that LPS selectively activates p38, but inhibits ERK and NF-B activity in treated cells. As NF-B is a common transcription factor of the Raf/MEK/ERK pathway (26, 27), it is conceivable that the reduced NF-B activity in LPS-treated cells was the result of a suppressed Raf/MEK/ERK cascade. Alternatively or concomitantly, the increased secretion of IL-10 by the treated cells could also be responsible for the decreased ERK and NF-B activities (28). As NF-B plays a pivotal role in DC differentiation, maturation, and function (27), it is plausible that the reduced NF-B activity was responsible for the retarded DC differentiation induced by LPS.
To further elucidate the mechanisms underlying LPS-induced inhibition of DC differentiation, we examined the cellular and molecular consequences following inhibition of endogenous cytokines, especially IL-10 and p38 MAPK, as these two molecules were the most likely contributors to the damage. In our study neutralizing Abs were used to block the activity of IL-6, TNF-, and IL-10 secreted by LPS-treated cells. As shown in Fig. 6, only blocking autocrine IL-10 partially restored the phenotype of LPS-treated cells, suggesting that IL-10 played a minimal role in the process. This is in line with previously published studies showing that exogenous IL-10 inhibited both DC differentiation and maturation (29, 30, 31) as well as IL-12 production (32). When the widely used p38 inhibitor, SB203580, was added to the culture, LPS-treated cells displayed almost normal morphology, phenotype, and function. SB203580 also inhibited LPS-induced secretion of IL-1, TNF-, and IL-10 and up-regulated the production of IL-12. Furthermore, the p38 inhibitor restored the activity of ERK and NF-B, without causing a significant change in STAT3 activity in LPS-treated cells. This is due to the inability of SB203580 to reduce the production of IL-6 by cells treated with LPS, as IL-6 binding with the IL-6R gp130 activates STAT3 (33, 34). Thus, these findings suggest that activation of p38 was largely responsible for LPS-induced inhibition in DC differentiation. Based on these results, we speculate that LPS binds with TLR-4 and/or CD14 on monocytes and activates the p38 MARK pathway, which, in turn, inactivates the Raf/MEK/ERK pathway and NF-B, leading to the inhibition of GM-CSF- and IL-4-induced differentiation of monocytes to DCs. LPS also induces cells to secrete IL-10, which further reduces the activity of NF-B. Hence, our study suggests that activation of p38 may be detrimental to DC differentiation and warrants further investigation to examine the roles of p38 and other MAPKs in the differentiation of DCs.
In conclusion, our study demonstrates that LPS is detrimental to the differentiation of immature DCs from monocytes. Addition of the bacterial endotoxin to monocyte culture retarded the generation of immature MoDCs, which was dependent on the activation of MAPK p38 and the secretion of IL-10, and the inactivation of ERK and NF-B. Addition of p38 inhibitor SB203580 almost completely abrogated the effects of LPS on generation of the cells. Thus, our study reveals that LPS has dual effects on DCs that both are biologically important. LPS activates existing immature DCs in vivo to initiate an immune response against the infection. LPS also inhibits the generation of new DCs so that the scale of the immune response can be limited to minimize damage to normal tissue. Hence, our study may shed light on the role of LPS as a potential regulator of the immune system.
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Qing Yi, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 776, Little Rock, AR 72205. E-mail address: yiqing{at}uams.edu
3 Abbreviations used in this paper: DCs, dendritic cells; AVG, average value of pixels enclosed; ERK, extracellular signal-regulated kinase, JNK, c-Jun N-terminal kinase, MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; PPD, purified protein derivative; MoDCs, monocyte-derived dendritic cells; pIB, phosphorylated IB; pp38, phosphorylated p38; pSTAT3, phosphorylated STAT3; TLR, Toll-like receptor.
Received for publication June 5, 2003. Accepted for publication August 22, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B. J. Immunol. 168:5491.. J. Exp. Med. 179:1109.B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039., and contact sensitizers. J. Immunol. 166:3837.B recruitment. Nat. Immunol. 3:69.[Medline]
B and primes DC for IL-12 production. Immunity 9:315.[Medline]
and prostaglandin E2. Blood 91:3112.
for lipopolysaccharide-induced IL-12 synthesis in monocyte-derived dendritic cells. Eur. J. Immunol. 32:3040.[Medline]
B-dependent pathway. J. Virol. 74:9617.B signaling pathway. J. Immunol. 170:3963.B subunits. Immunity 16:257.[Medline]
-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J. Immunol. 162:3865.This article has been cited by other articles:
|
|
 |
|
  Y. IWATA, K. FURUICHI, N. SAKAI, H. YAMAUCHI, Y. SHINOZAKI, H. ZHOU, Y. KUROKAWA, T. TOYAMA, S. KITAJIMA, T. OKUMURA, et al. Dendritic Cells Contribute to Autoimmune Kidney Injury in MRL-Faslpr Mice J Rheumatol, February 1, 2009; 36(2): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Marin-Esteban, M. Abdul, D. Charron, A. Haziot, and N. Mooney Dendritic Cells Differentiated in the Presence of a Single-Stranded Viral RNA Sequence Conserve Their Ability To Activate CD4 T Lymphocytes but Lose Their Capacity for Th1 Polarization Clin. Vaccine Immunol., June 1, 2008; 15(6): 954 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. U. A. Mollah, S. Pai, C. Moore, B. J. O'Sullivan, M. J. Harrison, J. Peng, K. Phillips, J. B. Prins, J. Cardinal, and R. Thomas Abnormal NF-{kappa}B Function Characterizes Human Type 1 Diabetes Dendritic Cells and Monocytes J. Immunol., March 1, 2008; 180(5): 3166 - 3175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Handley, J. Rasaiyaah, J. Barnett, M. Thakker, G. Pollara, D. R. Katz, and B. M. Chain Expression and function of mixed lineage kinases in dendritic cells Int. Immunol., August 13, 2007; (2007) dxm050v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Assier, V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation J. Leukoc. Biol., January 1, 2007; 81(1): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bartz, N. M. Avalos, A. Baetz, K. Heeg, and A. H. Dalpke Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation Blood, December 15, 2006; 108(13): 4102 - 4108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, S. Hong, J. Yang, J. Qian, X. Zhang, E. Shpall, L. W. Kwak, and Q. Yi Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells Blood, December 15, 2006; 108(13): 4071 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yasutomi, Y. Ohshima, N. Omata, A. Yamada, H. Iwasaki, Y. Urasaki, and M. Mayumi Erythromycin Differentially Inhibits Lipopolysaccharide- or Poly(I:C)-Induced but Not Peptidoglycan-Induced Activation of Human Monocyte-Derived Dendritic Cells J. Immunol., December 15, 2005; 175(12): 8069 - 8076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bracci-Laudiero, L. Aloe, M. C. Caroleo, P. Buanne, N. Costa, G. Starace, and T. Lundeberg Endogenous NGF regulates CGRP expression in human monocytes, and affects HLA-DR and CD86 expression and IL-10 production Blood, November 15, 2005; 106(10): 3507 - 3514. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
